Lynestrenol

Summary

Lynestrenol (CHEMBL2107431) is an approved small molecule (ATC G03AC02).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G03AC02 (+1 more)
• Clinical trials: 2
• Chemistry: 284.4 Da · C20H28O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107431
Name	Lynestrenol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5857
ATC	G03AC02, G03DC03
Molecular formula	C20H28O
Molecular weight	284.4
InChIKey	YNVGQYHLRCDXFQ-XGXHKTLJSA-N

SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CCCC[C@H]34

IUPAC name: (8R,9S,10R,13S,14S,17R)-17-ethynyl-13-methyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol

Also known as: Linestrenol, Lynestrenol, Lynoestrenol, NSC-37725, LYNESTRENOL, lynestrenol

Patent coverage: 1,228 distinct patent families (4,749 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Amine oxidase [flavin-containing] A, Progesterone receptor, Kappa-type opioid receptor.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 3 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
MAOA	6.52	AC50	300	nM	CHEMBL_ACT_25159424
OPRK1	5.82	AC50	1500	nM	CHEMBL_ACT_25129194
PGR	5.28	AC50	5200	nM	CHEMBL_ACT_25222843

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE4	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01065220	PHASE4	COMPLETED	Sex Steroids and the Serotonin Transporter
NCT02715232	PHASE4	UNKNOWN	Effects of Sex Steroids on the Serotonin System

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).